We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
A leading Eastern European contract research organization successfully completed the recruitment of 236 subjects in a Phase III osteoarthritis study for the Korean pharmaceutical manufacturer, Handok Inc., despite hurdles caused by the COVID-19 pandemic. They also managed to wisely deal with budget matters, for instance, allocating unused travel budgets to cover additional monitoring, remote monitoring hours, and the hours put in by data managers for query resolution. Apart from the immediate contribution to the overall research, the study has extended the knowledge of the efficacy and safety of an adhesive plaster for knee osteoarthritis. In the available case study, read about the hurdles and the solutions for overcoming them, as well as the major drivers of the study’s success.
Download the case study to find out the details of the study.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
